Kura Oncology (NASDAQ:KURA – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43, Zacks reports. The business had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million.
Kura Oncology Stock Up 0.2 %
Shares of KURA stock traded up $0.02 on Friday, reaching $7.67. 127,660 shares of the company were exchanged, compared to its average volume of 1,569,803. The company has a market cap of $596.06 million, a price-to-earnings ratio of -3.25 and a beta of 0.78. The company has a 50-day moving average of $8.19 and a 200-day moving average of $13.92. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a one year low of $6.98 and a one year high of $24.17.
Insider Buying and Selling
In other news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 in the last quarter. Insiders own 5.50% of the company’s stock.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Kura Oncology
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
See Also
- Five stocks we like better than Kura Oncology
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 5 Best Gold ETFs for March to Curb Recession Fears
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
- CD Calculator: Certificate of Deposit Calculator
- Why Smart Investors Are Watching These 3 Undervalued Stocks
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.